The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 535-541

  Patel, Keyur ^a   Albrecht, Jeff ^b   Owens, Erin ^b   Dev, Anouk ^a   Heaton, Shanon ^c   Pianko, Stephen ^c   Pockros, Paul J ^c   Conrad, Andrew ^b   Blatt, Lawrence M ^d   McHutchison, John G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b National Genetics Institute   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d InterMune Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATIONIC SURFACTANT; CATRIMOX 14; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TETRADECYLTRIMETHYLAMMONIUM OXALATE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUATERNARY AMMONIUM COMPOUNDS; RIBAVIRIN; RNA, VIRAL; SURFACE-ACTIVE AGENTS; TRIMETHYL AMMONIUM COMPOUNDS;

EID: 23044470264     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA & Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine 1999; 341:556-562.
2. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of Viral Hepatitis 1999; 6:35-47.
3. Detre KM, Belle SH & Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Reviews 1996; 2:219-228.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M & Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Graxi A, Lin A, Hoffman J & Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347:975-982.
6. Schmidt WN, Klinzman D, LaBrecque DR, Macfarlane DE & Stapleton JT. Direct detection of hepatitis C virus (HCV) RNA from whole blood, and comparison with HCV RNA in plasma and peripheral blood mononuclear cells. Journal of Medical Virology 1995; 47:153-160.
7. Schmidt WN, Wu P, Han JQ, Perino MJ, LaBrecque DR & Stapleton JT. Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load. Journal of Infectious Diseases 1997; 176:20-26.
8. Schmidt WN, Wu P, Brashear D, Klinzman D, Phillips MJ, LaBrecque DR & Stapleton JT. Effect of interferon therapy on hepatitis C virus RNA in whole blood, plasma, and peripheral blood mononuclear cells. Hepatology 1998; 28:1110-1116.
9. Cook L, Ross AM, Knight GB & Agnello V. Use of whole blood specimens for routine clinical quantitation of hepatitis C virus RNA does not increase assay sensitivity. Journal of Clinical Microbiology 2000; 38:4326-4331.
10. Brashear D, Taylor S, Xiang J, Klinzman D, LaBrecque F, Pfaller M, Alden B, LaBrecque D, Stapleton J & Schmidt W. 10th Triennial International Symposium of Viral Hepatitis Liver Disease. 9-13 April 2000, Atlanta, Georgia, USA. Abstract C008.
11. Chomczynski P & Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987; 162:146-159.
12. Tong MJ, Hwang SJ, Lefkowitz M, Lee SD, Co RL, Conrad A, Schmid P & Lo KJ. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. Journal of Gastroenterology & Hepatology 1994; 9:587-591.
13. Poynard T, McHutchison J, Goodman Z, Ling MH & Albrecht J. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-218.
14. Watkins-Riedel T, Ferenci P, Steindl-Munda P, Gschwantler M, Mueller C & Woegerbauer M. Early prediction of hepatitis C virus infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis. Clinical Infections Diseases 2004; 39:1754-1760.
15. Gowans EJ. Distribution of markers of hepatitis C virus infection throughout the body. Seminars in Liver Diseases 2000; 20:85-102.
16. MacFarlane DE & Dahle CE. Isolating RNA from clinical samples with catrimox-14 and lithium chloride. Journal of Clinical Laboratory Analysis 1997; 11:132-139.
17. Schmidt W, Wu P, Cederna J, Mitros F, LaBrecque D & Stapleton J. Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. Journal of Infectious Diseases 1997; 176:27-33.
18. Stapleton J, Klinzman D, Schmidt W, Pfaller M, Wu P, LaBrecque D, Han J, Perino-Phillips M, Woolson & Alden B. Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. journal of Clinical Microbiology 1999; 37:484-489.
19. Schmidt W, Stapleton J, LaBrecque D, Mitros F, Kirby P, Perino-Phillips M & Brashier D. Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology. Hepatology 2000; 31:737-744.